Thus, we conclude that FabC11:Stx2 is an encouraging therapeutic tool for neutralizing the effects of Stx2 and preventing HUS development, even though more investigations are needed regarding the efficacy of this protection in vivo. This evidence concerns the gene STX2 and hemolytic-uremic syndrome.